Welcome to our dedicated page for Fulcrum Therapeutics news (Ticker: FULC), a resource for investors and traders seeking the latest updates and insights on Fulcrum Therapeutics stock.
Fulcrum Therapeutics Inc (FULC) is a clinical-stage biopharmaceutical company pioneering therapies that address genetically defined rare diseases through precise gene regulation. This dedicated news hub provides investors and industry observers with essential updates on the company's scientific advancements and operational milestones.
Access real-time information about FULC's clinical programs, including losmapimod for facioscapulohumeral muscular dystrophy (FSHD) and pociredir for hemoglobin disorders. Our curated collection features official press releases, regulatory filings, and analysis of strategic partnerships that shape the company's trajectory in targeted therapy development.
Key updates include progress reports on clinical trials, FDA designations, research collaborations, and financial disclosures. Bookmark this page to monitor FULC's innovative approach to modulating gene expression and its potential impact on treating rare diseases with high unmet medical needs.
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in Goldman Sachs’ 45th Annual Healthcare Conference. Scheduled for June 10, 2024, at 10:00 a.m. ET, the company's management will engage in a fireside chat. A webcast of the presentation will be accessible via Fulcrum's website and available for replay for at least 30 days post-event. Fulcrum focuses on developing small molecules aimed at improving the lives of patients with genetically defined rare diseases.
Fulcrum Therapeutics, a biopharmaceutical company, announced recent business highlights and financial results for Q1 2024. They entered a collaboration with Sanofi for losmapimod, expect Phase 3 trial results in Q4 2024, appointed a new chief medical officer, and reported positive data on their Phase 2 study. Fulcrum's cash position decreased, with collaboration revenue at zero. R&D expenses increased, G&A expenses decreased, and net loss rose. Cash runway guidance extends into 2027.
Fulcrum Therapeutics has partnered with Sanofi for the development and commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD). Sanofi gains exclusive rights outside the U.S., while Fulcrum retains rights in the U.S. Fulcrum will receive an $80.0 million upfront payment, with potential milestones of $975.0 million and royalties. The collaboration combines Fulcrum's FSHD expertise with Sanofi's global reach.
Fulcrum Therapeutics, Inc. announced its participation in upcoming conferences, including the RBC Capital Market Global Healthcare Conference and the H.C. Wainwright 2nd Annual BioConnect Conference. The Company is focused on developing small molecules for genetically defined rare diseases.
Fulcrum Therapeutics, a biopharmaceutical company, published Phase 2b clinical trial results of losmapimod for FSHD in The Lancet Neurology. While not meeting the primary endpoint, losmapimod showed improvements in structural and functional outcomes, with Phase 3 data expected in Q4 2024.
Fulcrum Therapeutics, Inc. will host a conference call and webcast on May 13, 2024, to discuss its first quarter 2024 financial results and recent corporate developments. The company focuses on developing small molecules for rare diseases.
FAQ
What is the current stock price of Fulcrum Therapeutics (FULC)?
What is the market cap of Fulcrum Therapeutics (FULC)?
